Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 105, Issue 7, 2010, Pages 1551-1560

  Fontana, Robert J ^a   Bieliauskas, Linas A ^b,c   Back Madruga, Carla ^d   Lindsay, Karen L ^d   Litman, Heather J ^e   Lok, Anna S F ^a   Kronfol, Ziad ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NEW ENGLAND RESEARCH INSTITUTES   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT;

ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; COGNITION; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS;

EID: 77954423935     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.3     Document Type: Article

References (46)

1. Forton DM, Tomas HC, Murphy C A et al. epatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-439
2. Hilsabeck RC, Hassanein TI, Calrlson MD et al. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003;9:847-854
3. Weissen born K, Krause J, Bokemeyer M et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatology 2004;41:845-851
4. Fontana RJ, Bieliauskas LA, Back-Madruga C et al. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatology 2005; 43: 614-622
5. Mcandrew's MP, Farcnik K, Carlen P et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801-808
6. Radkowski M, Wilkinson J, Nowicki M et al. Search for hepatitis C virus negative strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76: 600-608
7. Murray J, Fishman SL, Ryan E et al. Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol 2008;14:17-27.
8. Forton DM, Hamilton G, Allsop J M et al. Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatology 2008; 49: 316-322
9. Hillsabeck RC, Hassanein TI, Ziegler EA et al. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 2005;11:16-22.
10. Amodio P, De Toni EN, Cavalletto L et al. Mood, cognition, and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. J Afect Disord 2005;84:93-98
11. Kraus M R, Schafer A, Wissman S et al. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther 2005;77:90-100.
12. Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005;19 (*Suppl 3): S174-8.
13. Fontana RJ, Bieliauskas LB, Lindsay KL et al. Cognitive function does not worsen during pegylated Interferon and ribavirin retreatment of chronic hepatitis C. Hepatology 2007;45:1154-1163
14. Perry W, Hislabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci 2008; 53: 307-321
15. Fontana RJ, Kronfol Z, Lindsay K L et al. Changesinmood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol 2008;103:2766-2775
16. DiBisceglie AM, Shifman ML, Everson G T et al. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. N Engl J Med 2008;359:2429-2441
17. Citro V, Milan G, Tripodi F S et al. Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection. J Gastroenterol 2007; 42: 79-82. (Pubitemid 46351428)
18. Lee WM, Dienstag JL, Lindsay KL et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon non-responders. Contemp Clin Trials 2004;25:472-492
19. Shifman M L, Ghany MG, Morgan T R et al.Impact of reducing peginter-feron alfa-2a and ribavirin dose during retreatment in patients with chronic Hepatitis C. Gastroenterology 2007;132:103-112
20. Hannay HJ, Levin HS. Selective reminding test: an examination of the equivalence of four forms. J Clin Exp Neuropsychol 1985; 7: 251-263
21. Trahan DE, Larrabee GJ. Continuous Visual Memory Test. Psychological Assessment Resources: Odessa, FL, 1988.
22. Benton A L, Hamsher K, Verney NR et al. Contributions to Neuropsycho- logical Assessment. Oxford University Press: New York, 1983.
23. Wechsler D. WAIS-R Manual. Psychological Corporation: New York, NY, 1981.
24. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Teory and Clinical Interpretation. Neuropsychology Press: Tucson, AZ, 1993.
25. Heaton R K. Wisconsin Card Sorting Test. P sych o lo gical A ssessm en t Resources: Odessa, FL, 1981.
26. Benton AL, Sivan AB, Hamsher K et al. Contributions to Neuropsychological Assessment. Oxford University Press: New York, NY, 1994.
27. Zachary RA. Shipley Institute of Living Scale. Western Psychological Services: Los Angeles, CA, 1991.
28. Bieliauskas L, Back-Madruga C, Lindsay KL et al. Clinical relevance of cognitive scores in patients with advanced f brosis. J Clin Exp Neuropsychol 2006;28:1346-1361
29. Heaton RK, Kirson D, Velin RA et al. The utility of clinical ratings for detecting cognitive change in HIV infection. Neuropsychology of HIV Infection. Oxford: New York, NY, 1994, 188-206.
30. Carey CL, Woods SP, Gonzalez R et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 2004;26:307-319
31. Wittchen HU. Reliability and validity studies of the WHO Composite Inter national Diagnostic Interview: a critical review. J Psychiatr Res 1994; 28: 57-84.
32. Beck AT, Steer RA, Brown GK. BDI-II Manual. The Psychological Corporation. Harcourt Brace and Company: San Antonio, TX, 1996.
33. Skinner HA, Sheu WJ. Reliability of alcohol use indices: the lifetime drinking history and the MAST. J Stud Alcohol 1982; 43: 1157-1170
34. Colie A, Maruf P, Darvy DG et al. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003;9:419-423
35. Afdhal NH, Levine R, Brown R et al. Colchicine versus peg-interferon alfa-2B long term therapy; results of the 4 year co-pilot trial. J Hepatol 2008 (abstract) 48 (Suppl 2) abstract #3.
36. Fartoux L, Degos F, Trepo C et al. Effect of prolonged Interferon therapy on the outcome of hepatitis C Virus related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol 2007; 5: 502-507
37. Houx PJ, Shepherd J, Blauw G -J et al. Testing cognitive function in elderly populations: the PROSPER study. J Neurol Neurosurg Psychiatry 2002;73:385-389
38. Belinger LJ, Gaydos B, Tangphao-Daniels O et al. Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol 2005;20:517-529
39. Bird CM, Papadopoulou K, Ricciardelli P et al. Monitoring cognitive changes: psychometric properties of six cognitive tests. Br J Clin Psychol 2004;43:197-210.
40. Paolo AM, Troster A, Ryan JJ. Test-retest stability of the Continuous Visual Memory Test in elderly persons. Arch Clin Neuropsychol 1998;13:617-621 (Pubitemid 28421917)
41. Snow KK, Bonkovsky H L, Fontana R J et al.Changesin health-related quality of life are associated with disease progression and peginterferon therapy in patients with advanced hepatitis C in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. (Abstract). Hepatology 2008; 48: 4: A265.
42. Amodio P, Del Piccolo F, Marchetti P et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999;29:1662-1667
43. Amodio P, Montagnese S, Gatta A et al. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004; 19: 253-267
44. Stewart CA, Smith GE. Minimal hepatic encephalopathy. Nat Clin Pract Gastroenterol Hepatol 2007;4:677-685
45. Montalban X, Rio J. Interferons and cognition. J Neurol Sci 2006;245:137-140
46. Arguedas M R, De Lawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003;48:1622-1626